Posts Tagged ‘induction therapy’

October 25, 2013

Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients

Renal transplantation for carefully selected HIV-positive patients has become well-accepted over the last decade. There remain concerns about the risk of overimmunosuppression in this group, due to their pre-existing immunodeficiency due to HIV infection. In this US registry study, HIV-positive patients actually had a higher risk of acute rejection than HIV-negative recipients, but this increased […]

No Comments Posted in Liver Transplantation, Renal Transplantation
June 21, 2013

Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial.

.   .   

This multicenter, randomized controlled trial assessed the efficacy, safety and incidence of CAV in de novo heart transplant patients receiving everolimus at two doses (1.5 mg/day or 3.0 mg/day in divided doses) with reduced-dose cyclosporine versus MMF with full-dose cyclosporine. The high dose everolimus group was terminated due to increased mortality. The lower dose everolimus […]

No Comments Posted in Cardiac Transplantation
June 14, 2011

Alemtuzumab induction in renal transplantation

.   .   

Alemtuzumab is a monoclonal antibody developed for treatment of lymphoma that profoundly depletes both T- and B-cells, and has been used off-label in transplantation. This randomized controlled trial compared alemtuzumab to induction with either thymoglobulin or basiliximab, and with rapid corticosteroid withdrawal. There were fewer acute rejections at one year with alemtuzumab compared to conventional […]

No Comments Posted in Renal Transplantation